Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $110.14 million. The enterprise value is $63.95 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 228.36 million shares outstanding. The number of shares has increased by 15.94% in one year.
| Current Share Class | 228.36M |
| Shares Outstanding | 228.36M |
| Shares Change (YoY) | +15.94% |
| Shares Change (QoQ) | +27.20% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 29.29% |
| Float | 177.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.50 |
| Forward PS | 8.16 |
| PB Ratio | 1.40 |
| P/TBV Ratio | 5.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.65, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.65 |
| Quick Ratio | 3.47 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.73% and return on invested capital (ROIC) is -18.58%.
| Return on Equity (ROE) | -26.73% |
| Return on Assets (ROA) | -12.53% |
| Return on Invested Capital (ROIC) | -18.58% |
| Return on Capital Employed (ROCE) | -21.64% |
| Revenue Per Employee | $123,364 |
| Profits Per Employee | -$241,675 |
| Employee Count | 77 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.15% in the last 52 weeks. The beta is 1.33, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -56.15% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 54.86 |
| Average Volume (20 Days) | 1,293,100 |
Short Selling Information
The latest short interest is 26.64 million, so 11.67% of the outstanding shares have been sold short.
| Short Interest | 26.64M |
| Short Previous Month | 22.03M |
| Short % of Shares Out | 11.67% |
| Short % of Float | 14.98% |
| Short Ratio (days to cover) | 14.76 |
Income Statement
In the last 12 months, LCTX had revenue of $9.50 million and -$18.61 million in losses. Loss per share was -$0.09.
| Revenue | 9.50M |
| Gross Profit | -3.31M |
| Operating Income | -21.48M |
| Pretax Income | -24.19M |
| Net Income | -18.61M |
| EBITDA | -20.87M |
| EBIT | -21.48M |
| Loss Per Share | -$0.09 |
Full Income StatementBalance Sheet
The company has $47.81 million in cash and $2.51 million in debt, giving a net cash position of $45.29 million or $0.20 per share.
| Cash & Cash Equivalents | 47.81M |
| Total Debt | 2.51M |
| Net Cash | 45.29M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 77.01M |
| Book Value Per Share | 0.36 |
| Working Capital | 37.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.09 million and capital expenditures -$565,000, giving a free cash flow of -$23.66 million.
| Operating Cash Flow | -23.09M |
| Capital Expenditures | -565,000 |
| Free Cash Flow | -23.66M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is -34.81%, with operating and profit margins of -226.11% and -195.90%.
| Gross Margin | -34.81% |
| Operating Margin | -226.11% |
| Pretax Margin | -195.62% |
| Profit Margin | -195.90% |
| EBITDA Margin | -219.70% |
| EBIT Margin | -226.11% |
| FCF Margin | n/a |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.94% |
| Shareholder Yield | -15.94% |
| Earnings Yield | -17.03% |
| FCF Yield | -21.65% |
Dividend DetailsAnalyst Forecast
The average price target for LCTX is $4.20, which is 770.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.20 |
| Price Target Difference | 770.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 59.14% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
LCTX has an Altman Z-Score of -2.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.09 |
| Piotroski F-Score | 3 |